Mar. 25 at 8:19 PM
$VCYT Veracyte says new data demonstrate accuracy of WGS-based platform
Veracyte announced new data showing that its whole-genome sequencing-based platform for minimal residual disease testing detected cancer in patients treated for muscle-invasive bladder cancer with more accuracy than ddPCR-based blood testing and earlier compared to standard imaging. The findings, from the large, independent, multicenter, interventional TOMBOLA trial, were shared in an oral presentation at the 40th Annual European Association of Urology Congress in Madrid by Iver Nordentoft, Ph.D., Aarhus University.
The new study involved 100 patients enrolled in the TOMBOLA trial who had MIBC and were undergoing standard-of-care neoadjuvant chemotherapy and radical cystectomy. Their blood samples were evaluated for circulating tumor DNA using both ddPCR-based and Veracyte's WGS-based MRD testing platform to detect disease recurrence. Patients also underwent imaging. At the 6-month milestone, in comparison to ddPCR, the Veracyte MRD testing platform had an equivalent and outstanding negative predictive value for cancer recurrence, while having a higher specificity.
Longer follow-up is required to determine the clinical impact of these results. The findings also showed that the Veracyte MRD testing platform detected cancer recurrence a median of 93 days sooner than imaging. In the ongoing trial, ctDNA-positive patients are treated with immunotherapy and followed for clinical response.
